Saturday, July 21, 2018 6:42:10 PM
So using a similar timetable, our observation time period (where data is still being collected I believe) for 2809 ends on Sept 25. If we had to wait 8 weeks for the topline data, that would put data somewhere around Nov 20 2018 for vk2809.
Here are the two unrelated thoughts I was putting across. So they will present the full data set for 5211 on Sept 30. They will technically have all of the data for vk2809 at that time... I mean it won't be super organized and everything, but they will have it all. I think that this is really genius timing on their part. I think that it's at least possible (totally guessing here) that they will want to know how good their vk2809 data is, before they make a final decision on how to proceed in partnering 5211. It would technically effect buyout considerations as well, having all the data from both trials. For that reason, I am scratching my head wondering if possibly we won't hear anything about 5211 partnership until at least around the time of the sept 30 conference. If they are sitting on two blockbuster drugs, with data readily available, buyout may seem like a more reasonable venue to go down. Partnering on 5211 before they have 2809 data may impact bigger companies abilities to move through buyout, etc. I also wonder if that's why they registered this massive shelf, wondering if maybe their goal isn't buyout? All just guesses.
So my unrelated ramblings about the options... So don't get me wrong, I'm not in a hurry to part with my shares, and I still have a relatively large position. But I have been eyeing the Nov $20 calls (and the $22.5 and the $25's as well). I mean, it's stupid to sell covered calls if they get bought out before they expire lol. But I don't think that they would actually sell the company before they technically announce the 2809 topline data. I just think that it's gonna be a really close call... what happens first... the Nov call options expiring, or the 2809 topline data being released. I mean it's gonna be real close in my opinion. On the clinicaltrials.gov website, I believe they might even list December as the release date anticipation. What I have been thinking about doing, is selling some Nov $20 and up strike price covered calls, and using the money that I make by selling them, to buy more VKTX stock. I wouldn't sell those covered calls though, until late sept or early october... because I think they may go up in price between now and then, with sept 30 conference data coming, and a potential MDGL buyout happening (if not sooner, maybe before then). So after these things boost the price, I just wonder how much higher than $20 we could possibly get in stock price, without actually knowing that the 2809 data is good (2809 data being released). And as a technical piece, when I have been selling covered calls these past few months, I used the money to buy VKTXW. For whatever reason, VKTXW is trading at face value and their is really no time premium being charged, so it makes no sense (to me at least) to buy VKTX, when you can buy VKTXW for the inherent value.
I'm not giving investment advice, and have no clue how all this will play out. All just my ramblings and thoughts, don't do what I do lol. Standard disclaimers on doing your own DD etc to everyone on here!
Hope all is well buddy. And yeah, I am equally intrigued by the MDGL buyout rumors. That spanish site seems like junk and has a history of bad calls, but this could be real. I mean, MDGL said they were entertaining talks awhile back, and this stuff takes awhile, but not too long. And anyone who is gonna buy them, is probably gonna want to buy them long before they have to meet with the FDA to discuss phase 3 designs, so the timing seems reasonable on this rumor, even if the site doesn't seem as reputable.
Anyone, just wanted to check in and say hello to all the fellow longs, and keep an intellectual discussion going. I never dreamed that all of this stuff would be setting up this well, when I first got into this stock. The timing on all of these catalysts, and MDGL's uncanny success to date, has been outrageous. August conference call, Sept 30 5211 data, potential 5211 partner at some point (maybe, who knows), and 2809 data within 1-2 months possibly after 5211 data. There is really no lull in there. Especially when considering their other pipeline stuff (which will probably have zero effect on share price with this big stuff looming, but who knows). And also news approaching from GTXI. It's like the perfect storm imho.
Glad to share the ride with everyone, hope all is well. Wishing everyone an enjoyable rest of the summer, take care all
Recent VKTX News
- Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update • PR Newswire (US) • 04/24/2024 08:05:00 PM
- U.S. Futures Display Mixed Results Amid Earnings, WTI and Brent Crude Prices Dip in June Futures Trading • IH Market News • 04/24/2024 11:31:20 AM
- Viking Therapeutics to Report Financial Results for First Quarter 2024 on April 24, 2024 • PR Newswire (US) • 04/17/2024 08:05:00 PM
- Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735 • PR Newswire (US) • 03/26/2024 11:03:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 12:54:02 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 12:52:22 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2024 09:52:52 PM
- Viking Therapeutics Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional Shares • PR Newswire (US) • 03/04/2024 09:45:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 03/01/2024 09:13:40 PM
- Viking Therapeutics Announces Pricing of $550 Million Public Offering of Common Stock • PR Newswire (US) • 02/29/2024 01:50:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/27/2024 10:21:23 PM
- Viking Therapeutics Announces Proposed Public Offering of Common Stock • PR Newswire (US) • 02/27/2024 09:19:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 12:04:52 PM
- Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity • PR Newswire (US) • 02/27/2024 12:03:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/10/2024 01:59:57 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/09/2024 09:01:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 12:40:13 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 12:38:45 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/08/2024 09:56:27 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/08/2024 09:33:26 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/07/2024 10:33:13 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/07/2024 10:24:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/07/2024 09:09:21 PM
- Viking Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update • PR Newswire (US) • 02/07/2024 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/01/2024 01:39:53 AM
FEATURED Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • Apr 25, 2024 8:52 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM